Fitzgerald Kevin Joseph, CSO & EVP, Head of Research, has demonstrated a pronounced selling bias in recent transactions involving Alnylam Pharmaceuticals (ALNY), according to SEC Form 4 filings. Over 94 reported trades spanning two companies, Fitzgerald has sold $11.3 million worth of shares compared to $972,220 in buys, with all 24 recent transactions being sales of ALNY stock. The selling activity intensified in early March 2026, with multiple disposals each day from March 2 through March 5. Notable transactions include a $231,408 sale on March 3 and a $128,110 sale on March 2, alongside numerous mid-sized disposals ranging from $24,366 to $107,803 during the same period.
The absence of any recent purchases and the concentrated selling of ALNY shares suggest a consistent reduction in Fitzgerald’s position in the biopharmaceutical company. The transactions, executed in rapid succession, indicate a deliberate unwinding rather than sporadic adjustments. While the filings do not disclose the reasons behind the sales, the pattern aligns with a broader trend of net disposition activity, given the nearly 12:1 ratio of sell-to-buy value across all reported trades. The lack of diversification—with all recent activity focused solely on ALNY—further underscores the targeted nature of these transactions.
AI-assisted summary